Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022

Rhea-AI Summary

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will disclose its 2022 Q3 financial results on November 9, 2022, after U.S. market close. A live audio webcast will follow at 4:30 p.m. ET, providing an analysis of the results along with a business update. Interested participants are encouraged to register ahead of time for the event. Jazz Pharmaceuticals focuses on developing transformative medicines in neuroscience and oncology for patients with serious diseases, and it operates in nearly 75 countries.

DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 third quarter financial results and provide a business and financial update.

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. 

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2022-third-quarter-financial-results-on-november-9-2022-301659063.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals report its Q3 2022 financial results?

Jazz Pharmaceuticals is set to report its Q3 2022 financial results on November 9, 2022.

What time is the Jazz Pharmaceuticals Q3 2022 financial results webcast?

The webcast for Jazz Pharmaceuticals' Q3 2022 financial results will begin at 4:30 p.m. ET.

How can I access the Jazz Pharmaceuticals Q3 2022 financial results webcast?

You can access the webcast by registering through the Jazz Pharmaceuticals Investors section on their website.

Where is Jazz Pharmaceuticals headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

In how many countries does Jazz Pharmaceuticals operate?

Jazz Pharmaceuticals operates in nearly 75 countries worldwide.